RA Capital Management

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Commons Clinic is a multi-specialty healthcare provider based in Austin, Texas, established in 2021. The clinic focuses on delivering seamless medical treatment through a coordinated approach involving elite physicians. It offers comprehensive specialty and surgical care programs in various areas including pain management, orthopedics, women's health, and men's health. By emphasizing efficient and improved patient care, Commons Clinic aims to enhance the overall healthcare experience for its patients.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

NanoMosaic is a biotechnology company focused on advancing early illness detection, prognostic monitoring, and biomarker identification through its innovative nanoneedle technology. The company's proprietary proteomic platform utilizes nanoneedles to enable precise protein detection and quantification. By integrating these capabilities onto a single chip, NanoMosaic aims to enhance the efficiency and accuracy of biomarker discovery and validation processes. This technology is designed to support the medical and healthcare industries in improving diagnostic capabilities and patient outcomes.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Covid Apollo is a Boston-based venture capital firm founded in 2020, focused on investing in the biotechnology and life sciences sectors. The firm specializes in identifying and developing innovative solutions for COVID-19 testing by leveraging its expertise in diagnostics. By connecting life sciences investment funds with specialized knowledge in diagnostics, Covid Apollo aims to scale and commercialize effective testing solutions to address public health needs.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Dimension Therapeutics, Inc. is a gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for rare and metabolic diseases associated with the liver. Founded in 2013, the company has a robust pipeline of gene therapy programs, including DTX101 and DTX201 for hemophilia B and A, respectively. Additionally, its portfolio encompasses DTX301 for ornithine transcarbamylase deficiency, DTX401 for glycogen storage disease type Ia, DTX501 for phenylketonuria, DTX701 for Wilson disease, and DTX601 for citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, gaining access to a significant portfolio of patents related to adeno-associated virus (AAV) therapeutics. This collaboration supports the company's aim to advance its gene therapy platform and enhance its product development capabilities in the treatment of rare diseases. Dimension Therapeutics operates as a subsidiary of Ultragenyx Pharmaceutical Inc. since November 2017.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, specializing in the development and commercialization of non-absorbed drugs aimed at treating renal, cardiovascular, liver, and metabolic diseases. Founded in 2008, the company focuses on creating highly selective ion-trap therapies using its proprietary zirconium silicate technology, which allows for the reduction of toxic electrolyte levels while maintaining overall electrolyte balance. Its lead product, ZS-9, is an insoluble, non-absorbed zirconium silicate currently in Phase III clinical trials for the treatment of hyperkalemia, a serious condition characterized by elevated potassium levels in the blood, often affecting patients with chronic kidney disease, hypertension, diabetes, or heart failure. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

CellScape Corporation (formerly Saryna Medical Corp) is a privately funded company headquartered in Newark, California, in the heart of the biotech corridor of the San Francisco Bay Area. The Company has developed whole fetal cell technology to transform prenatal genetic testing using a simple blood test. Their vision is to make comprehensive prenatal genetic testing available to every woman without requiring an invasive procedure that might put the fetus at risk. Their leadership team is accomplished in bringing innovative, cost-effective medical and molecular diagnostics to market.

OvaScience, Inc. is a fertility company focused on discovering and commercializing innovative treatment options for women experiencing infertility. Founded in 2011 and headquartered in Waltham, Massachusetts, OvaScience developed proprietary technology based on the identification of egg precursor (EggPC) cells, enabling new approaches to fertility treatments. Its key offerings include OvaPrime, which aims to restore a woman's natural egg production by utilizing her own EggPC cells; OvaTure, which matures these cells into fertilizable eggs outside the body without hormone stimulation; and AUGMENT, which enhances fertilization and pregnancy rates using mitochondria from the woman’s EggPC cells. The company’s technology is exclusively licensed from Harvard Medical School and Massachusetts General Hospital, and it has been supported by a team of experts in reproductive science and embryology. OvaScience was initially known as Ovastem, Inc. before rebranding in 2011. In December 2018, OvaScience was acquired by Millendo Therapeutics, marking a significant shift in its operational focus.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Genelabs Technologies Inc. is a biopharmaceutical company based in Redwood City, California, focused on the discovery and development of therapies for infectious diseases. Founded in 1983, the company aims to improve human health through targeted research on high-value projects. Its product pipeline includes initiatives for treating Hepatitis C, as well as late-stage clinical assets like an investigational vaccine for hepatitis E and Prestara, a drug for systemic lupus erythematosus. Genelabs has established collaborative agreements with notable organizations, including the Novartis Institutes for BioMedical Research and Genovate Biotechnology Co., Ltd., to advance its research efforts in combating Hepatitis C. In 2009, Genelabs Technologies was acquired by SmithKline Beecham Corporation, further integrating its capabilities within a larger pharmaceutical framework.

Allegiance Hospice Group specializes in providing hospice care to patients in the Merrimack Valley and Southeastern Massachusetts. The organization employs an interdisciplinary team that includes physicians, nurses, home healthcare aides, social workers, mental health workers, counselors, and volunteers. This team delivers comprehensive palliative care to individuals with terminal illnesses, ensuring that patients receive the necessary support and treatment to manage their conditions effectively. Allegiance Hospice is committed to enhancing the quality of life for its patients through compassionate care tailored to their specific needs.